Background: In this study, we developed integrative, personalized prognostic models for breast cancer recurrence and overall survival (OS) that consider receptor subtypes, epidemiological data, quality of life (QoL), and treatment. Methods: A total of 15 314 women with stage I to III invasive primary breast cancer treated at The University of Texas MD Anderson Cancer Center between 1997 and 2012 were used to generate prognostic models by Cox regression analysis in a two-stage study. Model performance was assessed by calculating the area under the curve (AUC) and calibration analysis and compared with Nottingham Prognostic Index (NPI) and PREDICT. Results: Host characteristics were assessed for 10 809 women as the discovery population (median follow-up = 6.09 years, 1144 recurrence and 1627 deaths) and 4505 women as the validation population (median follow-up = 7.95 years, 684 recurrence and 1095 deaths). In addition to the known clinical/pathological variables, the model for recurrence included alcohol consumption while the model for OS included smoking status and physical component summary score. The AUCs for recurrence and OS were 0.813 and 0.810 in the discovery and 0.807 and 0.803 in the validation, respectively, compared with AUCs of 0.761 and 0.753 in discovery and 0.777 and 0.751 in validation for NPI. Our model further showed better calibration compared with PREDICT. We also developed race-specific and receptor subtype-specific models with comparable AUCs. Racial disparity was evident in the distributions of many risk factors and clinical presentation of the disease. Conclusions: Our integrative prognostic models for breast cancer exhibit high discriminatory accuracy and excellent calibration and are the first to incorporate receptor subtype and epidemiological and QoL data.
Background: In this study, we developed integrative, personalized prognostic models for breast cancer recurrence and overall survival (OS) that consider receptor subtypes, epidemiological data, quality of life (QoL), and treatment. Methods: A total of 15 314 women with stage I to III invasive primary breast cancer treated at The University of Texas MD Anderson Cancer Center between 1997 and 2012 were used to generate prognostic models by Cox regression analysis in a two-stage study. Model performance was assessed by calculating the area under the curve (AUC) and calibration analysis and compared with Nottingham Prognostic Index (NPI) and PREDICT. Results: Host characteristics were assessed for 10 809 women as the discovery population (median follow-up = 6.09 years, 1144 recurrence and 1627 deaths) and 4505 women as the validation population (median follow-up = 7.95 years, 684 recurrence and 1095 deaths). In addition to the known clinical/pathological variables, the model for recurrence included alcohol consumption while the model for OS included smoking status and physical component summary score. The AUCs for recurrence and OS were 0.813 and 0.810 in the discovery and 0.807 and 0.803 in the validation, respectively, compared with AUCs of 0.761 and 0.753 in discovery and 0.777 and 0.751 in validation for NPI. Our model further showed better calibration compared with PREDICT. We also developed race-specific and receptor subtype-specific models with comparable AUCs. Racial disparity was evident in the distributions of many risk factors and clinical presentation of the disease. Conclusions: Our integrative prognostic models for breast cancer exhibit high discriminatory accuracy and excellent calibration and are the first to incorporate receptor subtype and epidemiological and QoL data.
Authors: F Efficace; L Biganzoli; M Piccart; C Coens; K Van Steen; T Cufer; R E Coleman; H A Calvert; T Gamucci; C Twelves; P Fargeot; A Bottomley Journal: Eur J Cancer Date: 2004-05 Impact factor: 9.162
Authors: Caprice K Christian; Joyce Niland; Stephen B Edge; Rebecca A Ottesen; Melissa E Hughes; Richard Theriault; John Wilson; Charles A Hergrueter; Jane C Weeks Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: Harvey J Murff; Daniel Byrne; Jennifer S Haas; Ann Louise Puopolo; Troyen A Brennan Journal: J Gen Intern Med Date: 2005-01 Impact factor: 5.128
Authors: Nancy K Janz; Mahasin S Mujahid; Sarah T Hawley; Jennifer J Griggs; Amy Alderman; Ann S Hamilton; John Graff; Steven J Katz Journal: J Cancer Surviv Date: 2009-09-16 Impact factor: 4.442
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Alaa M G Ali; Marjanka K Schmidt; Manjeet K Bolla; Qin Wang; M Gago-Dominguez; J Esteban Castelao; Angel Carracedo; Victor Muñoz Garzón; Stig E Bojesen; Børge G Nordestgaard; Henrik Flyger; Jenny Chang-Claude; Alina Vrieling; Anja Rudolph; Petra Seibold; Heli Nevanlinna; Taru A Muranen; Kirsimari Aaltonen; Carl Blomqvist; Keitaro Matsuo; Hidemi Ito; Hiroji Iwata; Akiyo Horio; Esther M John; Mark Sherman; Jolanta Lissowska; Jonine Figueroa; Montserrat Garcia-Closas; Hoda Anton-Culver; Mitul Shah; John L Hopper; Antonia Trichopoulou; Bas Bueno-de-Mesquita; Vittorio Krogh; Elisabete Weiderpass; Anne Andersson; Françoise Clavel-Chapelon; Laure Dossus; Guy Fagherazzi; Petra H Peeters; Anja Olsen; Gordon C Wishart; Douglas F Easton; Signe Borgquist; Kim Overvad; Aurelio Barricarte; Carlos A González; María-José Sánchez; Pilar Amiano; Elio Riboli; Tim Key; Paul D Pharoah Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-03-17 Impact factor: 4.254
Authors: Woojae Kim; Ku Sang Kim; Jeong Eon Lee; Dong-Young Noh; Sung-Won Kim; Yong Sik Jung; Man Young Park; Rae Woong Park Journal: J Breast Cancer Date: 2012-06-28 Impact factor: 3.588
Authors: G C Wishart; C D Bajdik; E Dicks; E Provenzano; M K Schmidt; M Sherman; D C Greenberg; A R Green; K A Gelmon; V-M Kosma; J E Olson; M W Beckmann; R Winqvist; S S Cross; G Severi; D Huntsman; K Pylkäs; I Ellis; T O Nielsen; G Giles; C Blomqvist; P A Fasching; F J Couch; E Rakha; W D Foulkes; F M Blows; L R Bégin; L J van't Veer; M Southey; H Nevanlinna; A Mannermaa; A Cox; M Cheang; L Baglietto; C Caldas; M Garcia-Closas; P D P Pharoah Journal: Br J Cancer Date: 2012-07-31 Impact factor: 7.640
Authors: Zhi Huang; Xiaohui Zhan; Shunian Xiang; Travis S Johnson; Bryan Helm; Christina Y Yu; Jie Zhang; Paul Salama; Maher Rizkalla; Zhi Han; Kun Huang Journal: Front Genet Date: 2019-03-08 Impact factor: 4.599
Authors: Rashmi K Murthy; Juhee Song; Akshara S Raghavendra; Yisheng Li; Limin Hsu; Kenneth R Hess; Carlos H Barcenas; Vicente Valero; Robert W Carlson; Debu Tripathy; Gabriel N Hortobagyi Journal: NPJ Breast Cancer Date: 2020-03-25